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ABSTRACT 
Background: 
Lactate is measured in hospital settings to identify patients with sepsis and severe infections, and 
guide initiation of early treatment. Point-of-care technology could facilitate measurement of lactate 
by first contact clinicians in the community, however there has been little research into its utility in 
these environments.   
Aim: 
To investigate the effect of using point-of-care lactate (at presentation to healthcare) on mortality 
and other clinical outcomes, in patients presenting with acute infections. 
Design and Setting: 
Studies comparing the use of point-of-care lactate testing to usual care in initial patient assessment 
at presentation to healthcare, were identified using a maximally sensitive search strategy of six 
electronic databases. 
Methods: 
Two independent authors screened 3640 records for eligibility, and extracted data from eligible 
studies.  Quality assessment for observational studies was performed using the ROBINS-I tool.   
Results: 
8 studies were eligible for inclusion (3161 patients).  Seven studies recruited from emergency 
departments and one from a pre-hospital aeromedical setting. 
Five studies demonstrated a trend towards reduced mortality with point-of-care lactate testing; 
three studies achieved statistical significance.  One study demonstrated a significant reduction in 
length of hospital stay, although another did not find any significant difference.  Two studies 
demonstrated a significant reduction in time to treatment for antibiotics and intravenous fluids.  
Conclusion: 
There is no high quality evidence to support the use of point-of-care lactate in community settings.  
However, the available evidence suggests a trend towards reduction in in-hospital mortality 
associated with point-of-care lactate testing.  RCT evidence from community settings is required to 
evaluate this potentially beneficial diagnostic technology.  
Systematic Review Registration Number: CRD42017046052 
Keywords: 
General Practice, Primary Health Care, Pre-hospital Care, Point-of-Care Testing, Lactate, Sepsis 
How this fits in: 
• Sepsis accounts for around 37,000 deaths annually in the UK. 
• Lactate is often measured in the hospital setting.  
• The availability of point of care lactate allows measurement in community and pre-hospital 
environments such as primary care. 
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• Point of care lactate in at presentation to healthcare may reduce mortality. The quality of 
evidence is low and no studies have been conducted in an Out-Of-Hours or General Practice 
setting.  
INTRODUCTION 
Sepsis is defined as the life-threatening organ dysfunction caused by a dysregulated host response to 
infection(1, 4).  Severe sepsis is thought to account for around 37,000 deaths annually in the UK(2) – 
more than breast, bowel and prostate cancer combined(3).  
Early recognition and treatment are key in preventing deaths from sepsis(4).  Until recently, the 
focus has been on timely management in secondary care, with the introduction of sepsis care 
bundles and early warning scores(3, 5). However, the latest NICE guidance recognises that systems 
need to extend to primary care, to facilitate timely recognition and prompt treatment(4).  In 
addition, improving outcomes from sepsis has been highlighted as a clinical priority by the RCGP(6) 
and NHS England(7). 
Lactate measurement is frequently used in hospital settings to identify critical medical illness 
including sepsis and severe infections, and to guide treatment. With the recent increase in 
availability of point-of-care (POC) testing technology, possibilities for earlier biochemical testing in 
community settings have arisen (8).  
Community clinicians, the first point of assessment for many patients with sepsis, are in need of 
guidance regarding the added value of POC lactate in these settings. There are potential 
disadvantages of using such a test earlier in the pathway, such as increasing the time taken for 
assessment, false reassurance in emerging septic shock or a much higher false positive rate in a 
setting of much lower prevalence leading to inappropriate care escalation.   
Accordingly, a systematic review was undertaken to evaluate whether the use of point-of-care 
lactate testing at first presentation to any healthcare in a population of adults and children setting 
with symptoms suggestive of serious bacterial infection, reduces mortality or improves other clinical 
outcomes or markers of quality of care, such as time to antibiotics and length of any subsequent 
hospital stay.  
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METHODS 
Search Strategy 
We searched MEDLINE (1946 to present), EMBASE (1974 to June 03 2016), Web of Science (1945 to 
present), CENTRAL (Issue 5 of 12, May 2016), Database of Abstracts of Review of Effects (Issue 2 of 4, 
April 2015) and the Cochrane Database of Systematic Reviews (Issue 6 of 12, June 2016) for relevant 
articles, using a maximally sensitive strategy. (Search strategy available in appendix A). 
We excluded animal studies, case reports, comments, letters and editorials. All other study types 
were included in the search strategy. We searched for studies in both children and adults. There 
were no limits on language or date of publication. We performed citation searches of all full-text 
papers retrieved, to identify other relevant studies.  
Data extraction 
Following exclusion of duplicate studies, all titles and abstracts were screened independently by two 
authors (GH, DM and RF), using the following inclusion criteria: Population: patients presenting to 
first assessment settings including community based healthcare and emergency departments (EDs), 
with symptoms suggestive of serious bacterial infection; Intervention: point-of-care lactate testing, 
Comparator: usual care; Outcomes: at least one patient outcome (eg mortality, time to treatment, 
length of stay). Purely diagnostic accuracy studies were excluded, given this review’s focus on clinical 
outcomes (and the potential circularity of lactate measurement being required for diagnosis of 
sepsis according to some existing definitions of sepsis).  The full texts of remaining articles were 
independently screened by pairings of two authors (GH, DM and EM) and reviewed for inclusion 
according to the specified criteria. Disagreements were resolved by discussion with a third reviewer.  
Two authors (DM and EM) independently extracted data using a proforma.  The full papers were 
used where possible (4 studies), with abstracts used if no full paper was available (4 studies). The 
primary outcome was mortality. Secondary outcomes included time to lactate result, time to 
antibiotic and IV fluid treatment, and length of stay. Authors were contacted for further clarification 
or missing data where necessary. 
Quality Assessment 
Quality assessment was undertaken independently by two authors (DM and EM) using the ROBINS-I 
tool for non-randomised studies of interventions(9). Quality was determined on a scale from low risk 
of bias (comparable to a well performed RCT), to critical risk of bias (too problematic to provide any 
useful evidence on the effects of the intervention). 
Data synthesis  
There were insufficient data with acceptable risk of bias to perform meta-analysis. 
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RESULTS 
Study Characteristics 
3644 titles and abstracts were screened with 65 articles subsequently assessed for eligibility (Figure 
1) (of which 32 were full texts, and 33 records where abstracts only were available); 57 studies were 
excluded; 31 did not specify point-of-care lactate testing, 21 lacked a comparator group, five 
provided insufficient data for inclusion. Eight studies (3161 patients) were included in the analysis 
(Table 1).   
Three “before and after”(10-12), and five observational cohort studies(13-17) were included.  In the 
cohort studies there was limited description of the nature of allocation to point of care testing 
versus control.  Seven studies recruited from emergency departments(10-12, 14-17); of these, 
four(14-17) examined only a sub-population admitted from ED to ICU (and of these, two(14-15) 
included only patients who were subsequently mechanically ventilated).  One study had a pre-
hospital setting(13), describing patients being transported by an aeromedical service. The studies, 
conducted in the USA (five), Singapore (two) and Finland (one), examined a total of 1,346 point-of-
care lactate results. Seven studies recruited from adult populations(10, 11, 13-17), and one from a 
paediatric population(12).  In two studies the primary focus was not on point-of-care lactate testing, 
but evaluation of sepsis treatment targets(17), and introduction of septic shock protocol(13). There 
were no studies undertaken in general practice settings, out-of-hours primary care or ambulance 
services. 
Methods of point-of-care lactate testing included arterial(17), venous(10-12), and fingerprick 
samples(13), and were unclear in three studies(14-16). Precise timing of point-of-care lactate 
measurement was also not specified in any study.  Average lactate levels ranged from 2.3–
3.9mmol/L in the three studies(11, 16, 17) reporting this, with no significant differences between 
intervention and control groups. One study used lactate of ≥2mmol/L as an inclusion criteria(11).  No 
indicators of illness severity (e.g. NEWS, APACHE) were available for between-study comparison.  
Lactate result handling was expressly described in two of the papers; in one, lactate levels ≥2 were 
immediately communicated to the attending physician, and patients with a level of ≥4 were 
escalated to a critical care area; all patients were tested again after 2 hours (11). In the pre-hospital 
aeromedical setting, point-of-care lactate results were reported on hospital arrival to the attending 
physician(13). 
 
Study Quality Assessment and Risk of Bias 
Study quality assessment and risk of bias is presented in Table 3.  All included studies were found to 
have a moderate or serious risk of bias. Key limitations identified included: study design (lack of 
parallel group randomised trials); lack of definition of allocation to “point-of-care” or “usual care” 
lactate testing in prospective cohort studies; use of cohorts enriched for effect due to underlying risk 
(particularly in cohorts examining ED data only for patients subsequently admitted to the ICU) and 
potential for confounding of effects due to simultaneous introduction of wider sepsis care bundles.  
Due to the study limitations identified, and lack of comparability across study cohorts and sampling 
methods, no valid meta-analysis of outcome data was possible, and thus outcomes are reported 
descriptively. 
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Effects on patient outcomes and healthcare processes 
Mortality 
Six studies examined the effect on in-hospital mortality (Table 4.1).  Three studies reported a 
significant reduction in mortality with point-of-care lactate testing (mortality of 6 vs 19%, 
p=0.02(11), OR 0.6, p=0.001(14) and OR 0.71, p=0.006(15)).  Two studies reported a non-significant 
trend towards reduction in mortality(12, 17). Only one study, in the aeromedical patient transport 
setting, did not demonstrate a trend towards reduced mortality with point-of-care lactate testing 
(55 vs 49%, p=0.78(13)).  Two studies additionally reported decreased in-ICU mortality (OR 0.65, 
p=0.004(14) and OR 0.64, p=0.005(15)). 
 
Time to Treatment 
Outcomes for intravenous (IV) fluid administration in five studies included time to IV fluids 
(minutes), receiving IV fluids in <1hour, and total volume of IV fluids received (Table 4.2). Two 
studies in ED patients demonstrated a significant reduction in time taken for patients to receive IV 
fluids; (median time of 72 v 55 minutes (p=0.03)(11); 48.8% v 35.5% receiving IV fluids in less than an 
hour p=0.001(13)). No significant difference in the total volume of IV fluids received was found in the 
two studies examining this (2000 vs 2500mls, p=0.71(11), and 3300 vs 5000mls, p=0.79(13)).    
Two studies of adult patients in ED demonstrated a statistically significant reduction in time to 
antibiotic administration with point-of-care lactate testing, with one study demonstrating 25% of 
patients receiving antibiotics in <1hour compared to 15.1%, (p=0.007)(14), and a second study 
quoting an odds ratio of 4.2 (95% CI 1.2-14.4) for receiving antibiotics in <3hours(16). However, a 
third study in a similar setting failed to find any significant difference in time to antibiotic 
administration (median time of 89 vs 97 minutes, p=0.59)(11).  
No significant change in the number of patients receiving blood transfusions, intubation, central 
venous catheter (CVC) line insertion, (nor time to CVC line insertion), were demonstrated in adult 
patients(13), although one study did report an odds ratio of 9.8 (95% CI 3.5-27.4) for measurement 
of CVP in ED with the introduction of point-of-care lactate testing(16). 
In the study of a paediatric population, the proportion of children receiving a fluid bolus within both 
1 hour and 15 minutes of ED arrival was significantly increased by implementation of an ED septic 
shock protocol and care guideline, which included a point-of-care lactate measurement (43% vs 79% 
and 10 vs 47% respectively, p<0.05)(12).  An improvement in proportion of paediatric patients 
receiving antibiotics in <3hours was also evident following implementation of this sepsis protocol, 
however insufficient data were available for sub-analysis of any effect due to point-of-care lactate 
testing alone(12). 
 
Length of stay  
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Three studies (11-13) examined length of stay (Table 4.2).  One demonstrated a significant reduction 
in median length of paediatric hospital stay, from 7.5 to 5.8 days (p <0.05)(12). Another (11) found 
no significant difference in duration across total hospital, ED or ICU length of stay; median hospital 
stay was one day less in patients with point-of-care lactate testing (7 vs 8 days, p=0.27), although 
rates of admission to the Intensive Care Unit were significantly lower in patients who had received 
point-of-care lactate testing (33% vs 51%, p=0.02)(11).  
A third study, in the pre-hospital aeromedical setting, demonstrated a significant increase in ED 
length of stay in the intervention group with pre-arrival point-of-care testing, from a mean time of 
216 to 396 minutes (p 0.02)(13); however they do not report subsequent hospital admission or 
length of stay following this.  
 
Time to available lactate result 
Two studies compared point-of-care to laboratory lactate testing. One study demonstrated a 
significant reduction in time to lactate result (from time of arrival) from a median of 122 minutes to 
34 minutes in an ED setting (p<0.001)(11); a second study quoted an odds ratio of 4.6 (95% CI 1.8-
11.5) for acquiring a lactate result in under an hour when using point-of-care testing(16).  
 
 
DISCUSSION 
Main findings 
This review identifies an important gap in the evidence needed to guide community clinicians 
regarding the clinical benefit of point-of-care lactate testing for suspected sepsis in community 
settings. There were no randomised controlled trials and no studies in primary care. The  
observational studies identified suffered from serious limitations, and represented very 
heterogeneous study populations. The majority of included patients were severely unwell, with 
confirmed sepsis or septic shock, and a significant proportion were admitted to ICU and 
mechanically ventilated.  
However, available evidence suggests that point-of-care lactate testing was associated with a trend 
towards decreased subsequent in-hospital mortality.  We found that point-of-care lactate testing at 
initial assessment was associated with a reduction in the time to IV fluids and in two studies time to 
IV antibiotics, as well as an expected reduction in time to result compared to laboratory lactate.  
Sepsis is a time critical condition: for every hour delay in IV antibiotic administration there is an 
estimated 8% increase in mortality (18). We found variable evidence of benefit on length of stay.  
 
Strengths and limitations 
This is the first systematic review to explore the evidence for the impact on mortality of point-of-
care lactate testing in suspected sepsis at initial healthcare assessment. We undertook a 
comprehensive literature search which is unlikely to have missed relevant studies.  
There are several limitations. There were no studies set in primary care (including out-of-hours 
general practice) and only one study  in a pre-hospital (highly specialised aeromedical) setting(13), 
which again was managing critically unwell patients. The remaining studies reported findings from 
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data collected from Emergency Department patients, of which four only included patients 
subsequently transferred to ICU. There are likely to be substantial differences, most notably in 
severity of illness, between patients presenting to Emergency Departments and those presenting to 
primary care. It is unclear to what extent the results from this study can be extrapolated to these 
settings.  
In addition, no randomised controlled trials were identified. The results we present therefore only 
suggest association between the intervention and outcome with no evidence of causality. In two of 
the studies(12, 17) point-of-care lactate was introduced alongside a number of additional 
interventions aimed at reducing mortality from sepsis, and it was not possible to determine the 
contribution of point-of-care lactate alone to improvements observed. A single paper(12) looked at a 
paediatric population and therefore we were unable to assess the influence of age on outcomes.  
 
Comparison with existing literature 
The NICE sepsis guidance from 2016 highlights that systems need to extend to primary care to 
facilitate early recognition and prompt treatment, and transfer of patients to the most appropriate 
location of care in a timely fashion (4). However, the identification of sepsis in a General Practice 
setting can be challenging. Use of vital sign recording has been highlighted as a key way to improve 
sepsis recognition in the community(3, 4, 7, 19), although the utility of scoring systems in primary 
care to identify sick patients is still debated(4). Despite this there will still be some patients with 
sepsis with normal observations that are missed. These individuals may however have an elevated 
lactate (cryptic shock) and evidence suggests their mortality rate is as high as in those with overt 
septic shock(19-21). Therefore, the addition of point-of-care lactate may be of value, and handheld 
meters have been suggested to be reliable when compared to laboratory based lactate assays(22, 
23). 
Furthermore, testing may inform decisions about administration of immediate antimicrobial 
treatment (for the most unwell), timing and speed of transfer to hospital, or appropriateness of 
alternatives to hospital admission. A recent systematic review of primary care physicians described a 
positive approach to the potential utility of point-of-care diagnostics in reducing diagnostic certainty 
and increasing more effective targeting of treatment. However, it highlighted the need for 
reassurance about accuracy and utility of testing – and the possibility of misleading results and 
resultant over-treatment(24). 
 
Implications for future research and practice 
At present there is a complete lack of evidence to support the use of point-of-care lactate testing in 
primary care, OOH primary or ambulance settings to improve patient outcomes. Furthermore the 
appropriate threshold and prognostic values for lactate may be different at first assessment in the 
community given that established thresholds have been validated in secondary care cohorts with a 
different spectrum of illness severity and more established pathophysiological change later in the 
course of an illness. Additionally, there are potential disadvantages of using such a test earlier in the 
pathway of care, such as increasing the time taken for assessment, false reassurance in emerging 
septic shock, or a much higher false positive rate in a setting of much lower prevalence leading to 
inappropriate care escalation.  Consideration must also be given to the potential cost of equipment, 
reagents and staff training, and the potential frequency of testing in primary care. 
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In the limited evidence base described in this review there are trends towards reduced mortality and 
reduced time to treatment which point to the potential for point-of-care lactate testing to support 
recognition of sepsis in the community, decreasing mortality, whilst avoiding unnecessary and costly 
admissions. However, despite the potential challenges of designing such a study to be undertaken in 
primary care, randomised controlled trial evidence from community settings is now required to 
evaluate this potentially beneficial diagnostic technology.   
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Figure 1: flowchart of included studies. 
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Table 1: Characteristics of included studies 
Study 
(Year) 
Study Design Setting Intervention 
(n) 
Control 
(n) 
Lactate 
measurement 
sample / device 
Outcome measures 
Singer 
(2015) 
(10) 
Before and After Emergency 
Department 
80 80 Venous sample; 
Portable i-STAT 
system (Abbot 
POC) 
POCL measurement 
Resource utilisation 
Total Hospital Costs 
Singer 
(2014) 
(11) 
Before and After Emergency 
Department 
80 80 Venous sample; 
Portable i-STAT 
system (Abbot 
POC) 
POCL measurement 
Time to lactate result 
Mortality 
Resource utilisation 
IV fluids 
Antibiotics 
Larsen  
(2011) 
(12) 
Before, During 
and After 
Paediatric 
Emergency 
Department 
192 55 Venous blood 
gas sample 
POCL measurement 
Mortality 
Resource utilisation 
Sepsis bundle compliance 
Total Hospital Costs 
Mullen 
(2014) 
(13) 
Prospective 
observational 
cohort  
Pre-hospital 
aeromedical 
20 39 Fingerstick; 
Lactate Plus 
POC device 
(Nova 
Biomedical) 
POCL measurement 
Mortality 
IV fluids 
Transfusion 
Intubation 
CVC line 
Maung 
(2014) 
(14) 
Observational 
cohort  
Emergency 
Department 
363 502 Not specified POCL measurement 
Mortality 
IV fluids 
Antibiotics 
Choong 
(2014) 
(15) 
Observational 
cohort  
Emergency 
Department 
609 821 Not specified POCL measurement 
Mortality 
Smith 
(2010) 
(16) 
Observational 
cohort 
Emergency 
Department 
29 181 Not specified POCL measurement 
Time to lactate result 
IV fluids 
Antibiotics 
CVC line 
Sepsis bundle compliance 
Varpula 
(2007) 
(17) 
Subanalysis; 
Prospective 
observational 
cohort 
Emergency 
Department, 
Intensive 
Care Unit 
53 39 Arterial blood 
gas sample 
POCL measurement 
Mortality 
Sepsis bundle compliance 
 
Table 2: Participant Characteristics 
Study 
(Year) 
Country N Age (years) Sex (% M) Sepsis (% 
of cohort) 
Medical inclusion criteria 
Singer 
(2015) 
(10) 
USA 160 71** 58 100 Included in sepsis registry, 
lactate ≥2, suspected 
infection, at least 2 SIRS 
criteria 
Singer 
(2014) 
(11) 
USA 160 71** 58 100 Included in sepsis registry, 
lactate ≥2, suspected 
infection, at least 2 SIRS 
criteria 
Larsen  
(2011) 
(12) 
USA 345 6** 49 100 Septic Shock, Sepsis (ICD9 
code at discharge) 
Mullen 
(2014) 
(13) 
USA 59 61* 56 91 “Critically ill”, medical 
patient 
Maung 
(2014) 
(14) 
Singapore 865 62.5* 59 58 Mechanically ventilated, 
in shock, presented via ED 
Choong 
(2014) 
(15) 
Singapore 1430 61.2* 60 43 Mechanically ventilated, 
admitted to ICU, via ED 
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Smith 
(2010) 
(16) 
USA 210 - 59 100 Suspected infection, 
Critically ill, Septic Shock, 
Admitted to ICU 
Varpula 
(2007) 
(17) 
Finland 92 57** 72 100 Septic Shock, admitted to 
ICU, community acquired 
sepsis 
 
Key: * Mean, **Median 
 
Table 3: Quality assessment and Risk of Bias  
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Table 3: Quality assessment. Risk of bias as assessed using ROBINS-I tool. Key: Low – comparable to a 
well performed RCT; Moderate - sound for a non-randomised study but not comparable to a well 
performed RCT; Serious – Important problems in this domain; Critical- Too problematic to provide any 
useful evidence on the effects of the intervention; NI – No information. 
 
Table 4.1: Results (A): Mortality 
Outcome Study Intervention 
Group, n/total  (%) 
Usual Care,  
n/total (%) 
p 
In-hospital 
Mortality  
Singer 2014 (11) 5/80 (6) 15/80 (19) 0.02           † 
 Larsen 2011* (12) 
 
9/192 (5) 6/55 (11) 0.11 
 Mullen 2014 (13) 11/20 (55) 19/39 (49) 0.78 
 
 Varpula 2007 (17) 
 
18/53 (34) 14/39 (36) 0.66 
 Maung 2014 (14) OR 0.6 (0.46-0.8 95% CI) p=0.001 with POCL testing 
 
 Choong 2014 (15)  0.71 (0.55-0.9 95% CI) p=0.006 with POCL testing 
 
 
Key: † Reaches statistical significance; *Larsen study figures derived from supplementary data provided by first author correspondence 
 
Table 4.2: Results (B): Time to treatment and length of stay.  
Outcome  
 
Study Intervention 
group 
Usual Care p 
Length of stay Length of 
hospital stay 
(days) 
Singer 2014 (11) 7 (3-13)** 8 (4-13)** 0.27  
  Larsen 2011 (12) 5.8** 7.5** <0.05         
† 
 Length of ED 
stay (mins) 
Singer 2014 (11) 352 (246-457)** 326 (249-436)** 0.5 
  Mullen 2014 (13) 396* 216* 0.02           
† 
 Length of ICU 
stay (days) 
Singer 2014 (11) 3 (2-6)** 4 (2-6)** 0.9 
Lactate result Time to 
lactate result 
(Mins) 
Singer 2014 (11) 34 (26-55)** 122 (82-149)** <0.001      
† 
 Lactate result 
in <1hour 
Smith 2010 (16) OR 4.6 (1.8-11.5 95% CI) with POCL testing 
IV Fluids Time to IV 
fluids (mins) 
Singer 2014 (11) 55 (34-83)** 71 (42-110)** 0.03         † 
 IV fluids in 
<1hour (%) 
Maung 2014 (14) 48.8 35.5 0.001       
† 
(17) 
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 Total volume 
IV Fluids (ml) 
Singer 2014 (11) 2000 (2000-
3125)** 
2500 (2000-
4000)** 
0.71 
  Mullen 2014 (13) 3300 5000 0.79 
 IV fluids 
(ml/kg) 
Smith 2010 (16) 29.3 ± 3.4* 17.8 ± 1.4* <0.01      † 
Antibiotics Time to Abx 
(mins) 
Singer 2014 (11) 89 (63-182)** 97 (55-160)** 0.59 
 Abx in <1hr 
(%) 
Maung 2014 (14) 25 15.1 0.007      † 
 Abx in <3hr  Smith 2010 (16) OR 4.2 (1.2-14.4) with POCL testing 
Transfusion Received 
transfusion 
(%) 
Mullen 2014 (13) 50 62 0.41 
 
Key: † Reaches statistical significance; * Mean, **Median (IQR) 
 
 
 
